Fig. 1: Kaplan–Meier curves of progression-free survival.

The 67 subjects were stratified by a study arm and tumour mutational burden (TMB), b study arm, TMB and tumour BRAF status or c experimental-arm assignment and the combination of TMB ≥9 or BRAF-V600E and C-reactive protein (CRP) within the reference limit when starting nivolumab versus all other combinations of strata.